PARP1 and cancer: Poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors are a class of drugs which have recently had an investigational growth in the cancer treatment setting due to the increasing understanding of the functions of PARP enzymes in DNA repair.